Investigation of the clinical, serological and genetic factors that determine primary non-response, loss of response and adverse drug reactions to Anti-TNF drugs in patients with active luminal Crohn's Disease - EXTENSION

Trial Profile

Investigation of the clinical, serological and genetic factors that determine primary non-response, loss of response and adverse drug reactions to Anti-TNF drugs in patients with active luminal Crohn's Disease - EXTENSION

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Jun 2016

At a glance

  • Drugs Adalimumab (Primary) ; Infliximab (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms PANTS-E
  • Sponsors AbbVie; Merck Sharp & Dohme
  • Most Recent Events

    • 23 Jun 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017.
    • 24 Oct 2015 Accrual to date is 19% according to United Kingdom Clinical Research Network record.
    • 11 Oct 2015 Accrual to date is 14% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top